Breaking News Instant updates and real-time market news.

APRI

Apricus Biosciences

$0.38

-0.011 (-2.81%)

07:47
04/12/18
04/12
07:47
04/12/18
07:47

Apricus Biosciences to meet with the FDA

Apricus has an end-of-review meeting with the FDA to discuss the New Drug Application (NDA) for Vitaros, a topical cream for treatment of erectile dysfunction, on April 12.

  • 12

    Apr

APRI Apricus Biosciences
$0.38

-0.011 (-2.81%)

04/26/17
RODM
04/26/17
INITIATION
Target $4
RODM
Buy
Apricus Biosciences initiated with a Buy at Rodman & Renshaw
Rodman & Renshaw analyst Raghuram Selvaraju started Apricus Biosciences with a Buy rating and $4 price target. The analyst sees near-term potential regulatory submission of Vitaros for approval in the U.S and views the company as a "substantially de-risked specialty pharmaceuticals play."
08/30/17
HCWC
08/30/17
NO CHANGE
Target $4.5
HCWC
Buy
Apricus approval could lead to Allergan takeover, says H.C. Wainwright
H.C. Wainwright analyst Raghuram Selvaraju raised his price target for Apricus Biosciences (APRI) to $4.50 from $4.00 after the company filed the resubmission of a new drug application with the FDA for Vitaros, a topical cream formulation of alprostadil for the treatment of erectile dysfunction. The shares closed yesterday up 2c to $1.50. The resubmission is on time and "constitutes a major milestone for the company," Selvaraju tells investors in a research note. The analyst raised his probability of success for Vitaros to 80% from 70% and reiterates a Buy rating on Apricus. He believes that Allergan (AGN), which has an opt-in agreement for Vitaros, may choose to acquire Apricus if the topical cream secures U.S. approval.
02/16/18
HCWC
02/16/18
DOWNGRADE
HCWC
Neutral
Apricus Biosciences downgraded to Neutral from Buy at H.C. Wainwright
02/16/18
HCWC
02/16/18
DOWNGRADE
Target $1
HCWC
Neutral
H.C. Wainwright downgrads Apricus to Neutral with $1 target
H.C. Wainwright analyst Raghuram Selvaraju downgraded Apricus Biosciences to Neutral from Buy after the company received a complete response letter from the FDA regarding Vitaros. The analyst cut his price target for the shares to $1.00 from $4.50. The stock in afternoon trading is down 66%, or $2.12, to $1.07.

TODAY'S FREE FLY STORIES

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.